Core Viewpoint - Sarepta Therapeutics is set to present three-year topline functional results from its Phase 3 study of ELEVIDYS for Duchenne muscular dystrophy on January 26, 2026 [1] Group 1: Company Overview - Sarepta Therapeutics is a leader in precision genetic medicine focused on rare diseases, particularly Duchenne muscular dystrophy [3] - The company is developing a robust portfolio of programs targeting muscle, central nervous system, and cardiac diseases [3] Group 2: Upcoming Event Details - A webcast and conference call will be held on January 26, 2026, at 8:30 am Eastern Time to discuss the study results [1] - The event will be available for live streaming on Sarepta's investor relations website, with a replay archived for one year [2] - Participants wishing to join by phone must register online to receive dial-in details [2] Group 3: Investor Information - Sarepta encourages investors to regularly check its website for important updates and information relevant to their interests [4]

Core Insights - Sarepta Therapeutics, Inc. is recognized as a leader in precision genetic medicine for rare diseases [1] - The company will present at the 30th Annual Congress of the World Muscle Society (WMS) 2025 Congress scheduled for October 7-11, 2025, in Vienna, Austria [1] - Presentations will include results from multiple studies related to the delandistrogene moxeparvovec clinical development program, as well as a real-world evidence study focusing on pulmonary function in advanced-stage patients [1]